KRTAP5-9

Across TCGA pan-cancer cohorts, KRTAP5-9 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of KRTAP5-9’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where KRTAP5-9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRTAP5-9 is over-expressed in tumor, although a few such as KIRP and PRAD show the opposite, repressed pattern.

UCEC, THCA, and LIHC are the cancer types where KRTAP5-9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRTAP5-9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	+0.771	<.001	6	view →
THCA	All	All	+0.294	<.001	5	view →
LIHC	All	All	+0.126	<.001	5	view →
KICH	All	All	+0.686	.001	4	view →
BRCA	All	All	+0.192	<.001	4	view →
KIRP	All	II,III,IV	−0.303	.017	3	view →
LUSC	All	All	+0.227	.015	2	view →
PRAD	All	All	−0.144	.004	2	view →
COAD	Female	IV	+0.749	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

KRTAP5-9–UCEC

Open the UCEC breakdown →